ANI Pharmaceuticals, Inc. (ANIP) vs Cronos Group Inc. (CRON)

ANI Pharmaceuticals, Inc. and Cronos Group Inc. are both Drug Manufacturers Specialty & Generic companies. ANI Pharmaceuticals, Inc. is the larger, with a market value of $1.7B against $1.2B — 1.4× the size. ANI Pharmaceuticals, Inc. trades at the lower P/E: 15.3× against 16.7×. Cronos Group Inc. grew revenue faster over the last twelve months: 37.5% against 30.9%. Cronos Group Inc. has the higher net margin (20.9% vs 11.0%) and the lower return on invested capital (−0.34% vs 11.3%). Across the 21 metrics below, ANI Pharmaceuticals, Inc. leads on 15 and Cronos Group Inc. on 6.

Valuation

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
P/E 15.32 16.70 20.14
P/S 1.60 6.97 2.25
P/B 2.62 1.12 1.90
Price to free cash flow 9.35 25.24 16.54
EV/EBITDA 7.62 36.04 12.29
EV/Sales 1.84 2.53 2.56
Earnings yield 6.53% 5.99% (2.99%)
Free cash flow yield 10.70% 3.96% 0.00%

Profitability

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
Gross margin 60.40% 45.86% 53.94%
Operating margin 15.37% (0.96%) 0.00%
Net margin 11.04% 20.91% 0.00%
Free cash flow margin 17.12% 27.61% 0.00%
Return on equity 20.88% 3.33% (0.40%)
Return on assets 7.61% 3.18% (3.32%)
Return on invested capital 11.30% (0.34%) 0.00%

Growth

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 30.90% 37.46% 10.01%
EPS growth (last fiscal year) 419.23% (118.18%) —
Revenue growth, 5-year CAGR 33.48% 25.70% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
Debt to equity 1.02 0.00 0.05
Current ratio 2.91 16.18 2.31
Net debt to EBITDA 1.59 337.10 0.85

Dividend

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ANIP CRON Drug Manufacturers Specialty & Generic median
Market cap 1.70b 1.22b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack